Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System

Next Previous
X
Search
Trial Profile

Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Capecitabine; Fluorouracil; Irinotecan
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Digestive system neoplasms; Gastrointestinal cancer; Oesophageal cancer; Rectal cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 22 Jan 2022 Results (n=21) assessing antitumor activity of trastuzumab plus irinotecan in pretreated patients with HER2-postive unresectable metastatic CRC and explore biomarkers for response and resistance to this treatment presented at the 2022 Gastrointestinal Cancers Symposium
    • 17 Jul 2019 Planned number of patients changed from 75 to 100.
    • 17 Jul 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top